Latest news about Bitcoin and all cryptocurrencies. Your daily crypto news habit.
The collaboration aims to create a zero-shot generative AI model that would work on creating new antibody therapeutics and enhancing existing ones.
The pharmaceutical company that developed one of the vaccines for COVID-19, AstraZeneca, will partner with a United States-based artificial intelligence (AI) biologics firm, Absci, to design an antibody for cancer.
According to a Financial Times report on Dec.
Related: AI in healthcare: New tech in diagnosis and patient care
Absci’s website claims its AI screens “billions of cells” each week, going from antibodies to wet “lab-validated candidates” in six weeks.
“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover.”
Absci CEO Sean McClain had also publicly confirmed the partnership, stating that AstraZeneca will help leverage its AI work, according to a Reuters report.
AI is gaining momentum in the healthcare industry, as it could significantly accelerate both innovative research and the accuracy of data analysis. In November, Hong Kong’s Hospital Authority revealed the launch of an AI pilot to combat multidrug-resistant organisms or superbugs.
Magazine: Real AI use cases in crypto: Crypto-based AI markets, and AI financial analysis
Disclaimer
The views and opinions expressed in this article are solely those of the authors and do not reflect the views of Bitcoin Insider. Every investment and trading move involves risk - this is especially true for cryptocurrencies given their volatility. We strongly advise our readers to conduct their own research when making a decision.